Huy Trinh Le, Bui My Hanh, Dinh Toi Chu, Xuyen Hoang Thi Hong
Department of Oncology, Hanoi Medical University Hospital, Hanoi, Vietnam.
Tuberculosis and Lung Disease Department, Hanoi Medical University, Hanoi, Vietnam.
Open Access Maced J Med Sci. 2019 Dec 10;7(24):4244-4249. doi: 10.3889/oamjms.2019.368. eCollection 2019 Dec 30.
In recent times, scientists have found new treatments for colorectal cancer patients.
The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in stage IV.
Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients.
The overall response rate of the treatment was 79.4%. The average progression-free survival was 13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very low at percentage.
The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable.
近年来，科学家们发现了针对结直肠癌患者的新疗法。
本研究旨在评估氟尿嘧啶/亚叶酸、奥沙利铂和伊立替康三联化疗方案（FOLFOXIRI）对IV期转移性结直肠癌患者的疗效和毒性。
对39例IV期结直肠癌患者进行了非对照临床试验。
治疗的总缓解率为79.4%。平均无进展生存期为13.4±9个月。第12个月和第24个月的总生存率分别为90%和76%。粒细胞减少的比例为48.9%，无3级或4级。血液学以外的副作用最常见的是肝毒性，发生率为52.5%，主要为1级。呕吐发生率为18.3%，均为1级。其他不良事件的发生率非常低。
FOLFOXIRI三联化疗方案在缓解率、总生存率和无进展生存率方面改善了转移性结直肠癌患者的治疗效果，且毒性水平可接受。
